Unit
- Definition: A clinical trial is a research study conducted with human volunteers to evaluate the safety, efficacy, and optimal use of medical interventions such as drugs, devices, or biologics. These studies follow strict protocols and regulatory oversight.
- Phases: Phase I tests safety and dosage in 20-80 healthy volunteers; Phase II assesses efficacy and side effects in 100-300 patients; Phase III confirms effectiveness in 1,000-3,000 participants; Phase IV monitors long-term safety after market approval.
- Interventional vs. Observational: Interventional trials assign participants to specific treatments or procedures; observational studies observe outcomes without assigning interventions. Most drug trials are interventional and randomized.
- Randomization: Participants are randomly assigned to treatment or control groups to minimize bias. Randomization ensures that known and unknown confounding factors are balanced across groups.
- Blinding: Single-blind studies hide treatment assignment from participants; double-blind studies hide it from both participants and investigators. Blinding reduces expectation bias and strengthens results.
- Control Groups: The control group receives placebo, standard care, or no intervention to provide a baseline for comparison. Placebo controls are common in phase III trials, but active controls are used when placebo is unethical.
- Endpoints: Primary endpoints are the main outcome measures (e.g., survival, blood pressure reduction); secondary endpoints provide additional insights (e.g., quality of life). Surrogate endpoints (e.g., cholesterol level) are sometimes used.
- Protocol: Each trial follows a detailed protocol describing objectives, design, eligibility criteria, interventions, assessments, and statistical analysis. The protocol is approved by ethics committees and regulatory authorities before enrollment begins.
- Inclusion and Exclusion Criteria: Protocols define strict eligibility criteria to standardize the study population. Inclusion criteria specify required characteristics like age or disease stage; exclusion criteria remove individuals with conditions that could increase risk or confound results. These criteria protect participant safety and data integrity.
- Adverse Event Monitoring: Investigators systematically document all adverse events and serious adverse events during the trial. Serious adverse events require expedited reporting to ethics committees and regulators. This ongoing surveillance safeguards participant well-being and supports risk benefit evaluations throughout the study.
- Data and Safety Monitoring Board: An independent DSMB reviews interim data at planned intervals to assess safety and efficacy. The board can recommend stopping the trial early if risks outweigh benefits or if clear evidence of benefit emerges. This oversight upholds ethical standards and scientific validity.
Terminology
- Investigational Medicinal Product (IMP)
- A pharmaceutical form of an active ingredient or placebo being tested in a clinical trial, including products with a marketing authorization but used in new ways.
- Case Report Form (CRF)
- A paper or electronic record designed to capture all required data from each trial participant as specified by the protocol.
- Informed Consent Form (ICF)
- A document that outlines the trial's purpose, procedures, risks, benefits, and participant rights, signed by participants before enrollment.
Quick Revision
- Clinical trials are systematic studies in humans to evaluate medical interventions, following a predefined protocol and regulatory oversight.
- The four phases of drug development move from safety testing (Phase I) to post-marketing surveillance (Phase IV).
- Randomization and blinding are key methods to reduce bias and ensure objective results.
- Endpoints define what is measured, and the protocol governs every aspect of the trial.